On April 17, recently, Daniel stock Andon Health Co.Ltd(002432) ( Andon Health Co.Ltd(002432) ) issued another announcement and received a total of US $411 million, or about RMB 2.623 billion, from the US ACC (US Army contract management command) to the company’s US subsidiary on April 14.
The reporter learned that Andon Health Co.Ltd(002432) and American ACC signed an order of US $1.775 billion in January this year, and the company has completed all delivery obligations. American ACC has paid US $1.521 billion in total, and US $254 million has not been paid.
A few days ago, on April 12, Andon Health Co.Ltd(002432) just released the performance forecast for the first quarter of 2022. From January to March 2022, it realized a net profit of 14 billion yuan to 16 billion yuan, an increase of 400 times compared with the same period of the previous year, which is equivalent to making 170 million yuan a day, which is comparable to the money printing machine. After that, the share price gained three limit boards. However, the company’s share price went out of the “sky floor” trend last Friday.
American ACC paid US $411 million to the company
On April 17, Andon Health Co.Ltd(002432) disclosed the major contract progress of the daily operation of the U.S. subsidiary: American ACC paid a total of US $411 million to the company’s U.S. subsidiary, about RMB 2.623 billion. ACC has paid a total of US $1.521 billion, or 9.715 billion yuan, to its US subsidiary.
Andon Health Co.Ltd(002432) the contract with American ACC dates back to the beginning of this year.
Since January 2022, the company has quickly signed large orders with a total amount of more than 10 billion yuan within three days. One is the purchase orders and contracts for ihealth kits from New York and Massachusetts received by the U.S. subsidiary, with a cumulative amount of more than 2.1 billion yuan; The other is the ihealth kit product purchase contract signed by the US subsidiary and the US ACC, with a total amount of about RMB 8.102 billion.
With regard to the demand of various concerns, Andon Health Co.Ltd(002432) in an institutional survey on February 14, said that the relaxation of epidemic prevention and control measures in some European countries does not mean that the demand for covid-19 testing and treatment will disappear out of thin air. Under the circumstances of lifting restrictions in public places and resumption of production and classes in enterprise schools, there may be more application scenarios of self-testing. In addition, the company is actively contacting and communicating with customers in the Japanese market in order to open the Japanese market through private brand sales as soon as possible.
According to the survey records, Andon Health Co.Ltd(002432) in the peak production scheduling period, the delivery cycle of commercial orders is 6-8 weeks. The company’s current delivery scheduling has been shortened. According to the current scheduling plan, it will be able to meet the needs of government and commercial customers as planned. At the same time, the company also plans to separate the testing business and establish an independent testing organization to serve customers with relevant testing and certification needs.
The company also revealed that after ihealth kit products became the mainstream products of the kit, its ihealth brand also became the mainstream brand in the United States. Ihealth’s U.S. subsidiary also sponsored the organizer of the American Football Super Bowl to distribute the kit products to more than 70000 spectators.
This was followed by a series of delivery Announcements:
On the morning of February 10, Andon Health Co.Ltd(002432) announced that the company’s US subsidiary had delivered 105 million copies of ihealth kit products to the contract counterparty. American ACC paid a total of 108 million US dollars to the company’s US subsidiary on February 7, 2022 local time for 211680 million copies of ihealth kit products. The above payment has been received, about 687 million yuan.
On February 17, Andon Health Co.Ltd(002432) announced that according to the delivery arrangement in the main contents of the contract, as of February 15, 2022 local time in the United States, the company’s U.S. subsidiary had delivered 177 million copies of ihealth kit products to the contract counterparty. ACC of the United States has paid a total of US $465 million to the company’s US subsidiary. All the above payments have been received on February 16, us time, about 2.95 billion yuan.
On March 10, Andon Health Co.Ltd(002432) announced that as of March 9, 2022 local time in the United States, the company’s U.S. subsidiary had delivered about 354 million copies of ihealth kit products to the contract counterparty ACC in the United States. So far, the company’s U.S. subsidiary has fulfilled the delivery obligation of the above contract. At present, a total of about US $465 million has been received for the kit products for about 911374 million people.
This also means that for the order of USD 1.775 billion between Andon Health Co.Ltd(002432) and American ACC, the company has completed all delivery obligations, and American ACC has paid USD 1.521 billion in total.
Xiaomi holds 20% of the shares of its “banknote printer” subsidiary
It has been three years since covid-19 epidemic broke out in the world. During this period, most industries suffered from it, but some stocks in the medical industry took off against the trend, and their share prices and performance soared breakthrough, Andon Health Co.Ltd(002432) is one of them.
According to the market data, Andon Health Co.Ltd(002432) share price started from November 2021, and its closing price was 6.80 yuan / share on November 12 last year. In the following five months, the share price rose more than 10 times, which is amazing. As of the latest, Andon Health Co.Ltd(002432) reported 81.10 yuan / share, with a market value of 39 billion yuan.
Andon Health Co.Ltd(002432) was established in 1995 and was listed on Shenzhen small and medium-sized board in June 2010 Andon Health Co.Ltd(002432) ‘s rise came from the New Coronavirus Labs self testing OTC kit of its US subsidiary iHealth Labs Inc., which has obtained the US Food and drug administration emergency response authorization (EUA), and the US state government and the federal government have contributed a large number of orders to Andon Health Co.Ltd(002432) .
According to the forecast of Andon Health Co.Ltd(002432) first quarterly report, it is estimated that the net profit attributable to the parent company in the first quarter of 2022 will be 14-16 billion yuan, with a year-on-year increase of 3670743% – 4196563%. The reason for the significant increase in performance is that its US subsidiary sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
It is worth mentioning that Xiaomi owns 20% of ihealth, an American subsidiary comparable to money printing machine. According to the data on Xiaomi’s official website, Andon Health Co.Ltd(002432) once obtained a strategic investment of US $25 million from Xiaomi technology and became a partner of Xiaomi’s ecological chain; In September 2017, Xiaomi company released the ihealth forehead thermometer product, which is called “born for fever”.
According to the 2020 annual report, ihealth Inc. is a company established by Andon Health Co.Ltd(002432) and Xiaomi to carry out strategic cooperation in the field of mobile medicine. Founded in 2015, Andon Health Co.Ltd(002432) has adjusted ihealth’s global business under the structure of ihealth Inc. As of March 30, 2018, Xiaomi investment has received all the investment funds of $25 million. After this capital increase, the company holds 80% of its equity and Xiaomi investment holds 20% of ihealth Inc.
(screenshot from Andon Health Co.Ltd(002432) 2020 annual report)
In addition, Andon Health Co.Ltd(002432) also mentioned in the 2020 annual report that at the beginning of the establishment of ihealth brand, the company received strong support from apple and set up a subsidiary in the United States.
has not obtained the approval of Chinese antigen self-test products
In addition to Andon Health Co.Ltd(002432) , many domestic covid-19 home self-test kits have been approved by FDA in the United States, including Hangzhou Aikang, Zhejiang Orient Gene Biotech Co.Ltd(688298) , Xiamen Bosheng biology, etc. Zhejiang Orient Gene Biotech Co.Ltd(688298) is also an A-share listed company. Its products were authorized by EUA in the United States at the end of December 2021. At present, the performance of the first quarter of 2022 has not been disclosed.
On March 11, 2022, the covid-19 joint prevention and control comprehensive group of the State Council issued the notice on printing and distributing the application scheme of covid-19 virus antigen detection (Trial), which will be supplemented by antigen detection on the basis of nucleic acid detection in order to further optimize the covid-19 detection strategy and serve the needs of epidemic prevention and control.
As of March 29, the State Food and drug administration has approved 20 covid-19 virus antigen detection reagent products. At present, more than 20 covid-19 antigen self-test products have been approved in China, but Andon Health Co.Ltd(002432) has not been approved.
